Bridge Life Sciences Deep Dive Q&A with CEO, Nicole van der Weerden

Following on from her presentation during Bridge Life Sciences inaugural 'Targeting Cancer' webinar, our CEO Dr Nicole van der Weerden was back with Chris Kallos, CFA and Jane Lowe on Monday 16 November talking more in depth about Arovella’s cell therapy platform.

Key discussion points include:

  • Clinical updates on lead blood cancer program ALA-101

  • Expansion opportunities into autoimmune diseases

  • Preclinical progress for solid tumour program ALA-105

  • Funding runway and key milestones over the next 12 months

View recording

 
Next
Next

Dr Nicole van der Weerden on the Bridge Life Sciences Executive Series webinar